This evolution demands a higher level of public understanding and responsible dialogue
April - June 2022 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
GHK-Cu is naturally occurring in the human body and is generally very well tolerated
Renal function, however, is critical for acamprosate use, as it is renally cleared
As of December 31, 2025, we had $548.7 million in cash, cash equivalents, and marketable securities, which we believe will be sufficient to fund our operations and capital expenditure requirements at least into 2029
Despite these beneficial metabolic effects, native GLP-1 has significant pharmacokinetic limitations that restrict its therapeutic utility